Advertisement

Regional Melanoma Therapy: Positive Sentinel Lymph Node

Chapter
  • 172 Downloads

Abstract

Most cases of melanoma nodal metastasis are now diagnosed though sentinel lymph node biopsy. This is an earlier point in disease progression and carries a much more favorable prognosis than was the case in earlier eras when larger, clinically-apparent disease was more common. When sentinel lymph node metastases are discovered, patients are faced with a set of questions about the possible use of additional regional and systemic treatments. Recent and ongoing research continue to inform such decisions.

Keywords

Melanoma Lymph node Sentinel lymph node Micrometastasis Lymphadenectomy 

References

  1. 1.
    Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017a;67:472–92.CrossRefGoogle Scholar
  2. 2.
    Balch CM, Soong SJ, Gershenwald JE, et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013;20:3961–8.CrossRefGoogle Scholar
  3. 3.
    Callender GG, Gershenwald JE, Egger ME, et al. A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. J Am Coll Surg. 2012;214:608–17; discussion 617–9.CrossRefGoogle Scholar
  4. 4.
    Gershenwald JE, Scolyer RA, Hess KR. Melanoma of the skin. In: Amin MB, Edge SB, Greene FL, editors. AJCC cancer staging manual. New York: Springer International Publishing; 2017b. p. 563–85.CrossRefGoogle Scholar
  5. 5.
    Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211–22.CrossRefGoogle Scholar
  6. 6.
    Verver D, van Klaveren D, van Akkooi ACJ, et al. Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. Eur J Cancer. 2018;96:25–33.CrossRefGoogle Scholar
  7. 7.
    Aloia TA, Gershenwald JE, Andtbacka RH, et al. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol. 2006;24:2858–65.CrossRefGoogle Scholar
  8. 8.
    Gold JS, Jaques DP, Busam KJ, et al. Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. Ann Surg Oncol. 2007;14:2133–40.CrossRefGoogle Scholar
  9. 9.
    Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103:129–42.CrossRefGoogle Scholar
  10. 10.
    Morton D, Wen D, Wong J, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.CrossRefGoogle Scholar
  11. 11.
    Leung AM, Morton DL, Ozao-Choy J, et al. Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. JAMA Surg. 2013;148:879–84.CrossRefGoogle Scholar
  12. 12.
    Lee JH, Essner R, Torisu-Itakura H, et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol. 2004;22:3677–84.CrossRefGoogle Scholar
  13. 13.
    Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:757–67.CrossRefGoogle Scholar
  14. 14.
    Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.CrossRefGoogle Scholar
  15. 15.
    Shen P, Conforti AM, Essner R, et al. Is the node of Cloquet the sentinel node for the iliac/obturator node group? Cancer J. 2000;6:93–7.PubMedGoogle Scholar
  16. 16.
    Strobbe LJ, Jonk A, Hart AA, et al. The value of Cloquet’s node in predicting melanoma nodal metastases in the pelvic lymph node basin. Ann Surg Oncol. 2001;8:209–14.PubMedGoogle Scholar
  17. 17.
    Jakub JW, Terando AM, Sarnaik A, et al. Safety and feasibility of minimally invasive inguinal lymph node dissection in patients with melanoma (SAFEMILND): report of a prospective multi-institutional trial. Ann Surg. 2017;265:192–6.CrossRefGoogle Scholar
  18. 18.
    Postlewait LM, Farley CR, Diller ML, et al. A minimally invasive approach for inguinal lymphadenectomy in melanoma and genitourinary malignancy: long-term outcomes in an attempted randomized control trial. Ann Surg Oncol. 2017;24:3237–44.CrossRefGoogle Scholar
  19. 19.
    Postlewait LM, Farley CR, Seamens AM, et al. Morbidity and outcomes following axillary lymphadenectomy for melanoma: weighing the risk of surgery in the era of MSLT-II. Ann Surg Oncol. 2018;25:465–70.CrossRefGoogle Scholar
  20. 20.
    Delman KA, Kooby DA, Ogan K, et al. Feasibility of a novel approach to inguinal lymphadenectomy: minimally invasive groin dissection for melanoma. Ann Surg Oncol. 2010;17:731–7.CrossRefGoogle Scholar
  21. 21.
    Cochran AJ, Wen DR, Huang RR, et al. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol. 2004;17:747–55.CrossRefGoogle Scholar
  22. 22.
    Murali R, Desilva C, Thompson JF, et al. Non-sentinel node risk score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol. 2010;28:4441–9.CrossRefGoogle Scholar
  23. 23.
    Wevers KP, Murali R, Bastiaannet E, et al. Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients. Eur J Surg Oncol. 2013;39:179–84.CrossRefGoogle Scholar
  24. 24.
    Dewar DJ, Newell B, Green MA, et al. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol. 2004;22:3345–9.CrossRefGoogle Scholar
  25. 25.
    Starz H, Balda BR, Kramer KU, et al. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer. 2001;91:2110–21.CrossRefGoogle Scholar
  26. 26.
    van Akkooi AC, Verhoef C, Eggermont AM. Importance of tumor load in the sentinel node in melanoma: clinical dilemmas. Nat Rev Clin Oncol. 2010;7:446–54.CrossRefGoogle Scholar
  27. 27.
    Coit DG, Thompson JA, Algazi A, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14:450–73.CrossRefGoogle Scholar
  28. 28.
    Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16:1049–60.CrossRefGoogle Scholar
  29. 29.
    Ives NJ, Suciu S, Eggermont AMM, et al. Adjuvant interferon-alpha for the treatment of high-risk melanoma: an individual patient data meta-analysis. Eur J Cancer. 2017;82:171–83.CrossRefGoogle Scholar
  30. 30.
    Kirkwood J, Manola J, Ibrahim J, et al. A pooled analysis of Eastern Cooperative Oncology Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670–7.CrossRefGoogle Scholar
  31. 31.
    Eggermont AM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012;48:218–25.CrossRefGoogle Scholar
  32. 32.
    Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.Google Scholar
  33. 33.
    Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.CrossRefGoogle Scholar
  34. 34.
    Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845–55.CrossRefGoogle Scholar
  35. 35.
    Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789–801.CrossRefGoogle Scholar
  36. 36.
    Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824–35.CrossRefGoogle Scholar
  37. 37.
    Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813–23.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2021

Authors and Affiliations

  1. 1.Department of SurgeryCedars-Sinai Medical Center, The Angeles Clinic and Research InstituteLos AngelesUSA

Personalised recommendations